WENDY KEITEL to Middle Aged
This is a "connection" page, showing publications WENDY KEITEL has written about Middle Aged.
Connection Strength
0.474
-
A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
Score: 0.042
-
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
Score: 0.032
-
Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons =18 Years Old. J Infect Dis. 2015 Aug 15; 212(4):552-61.
Score: 0.031
-
Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen. BMC Infect Dis. 2013 Jun 19; 13:276.
Score: 0.027
-
Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
Score: 0.026
-
Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12.
Score: 0.025
-
Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin. 2009 Aug; 5(8):536-44.
Score: 0.021
-
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008 Nov 01; 198(9):1309-16.
Score: 0.020
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
Score: 0.015
-
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019 12 13; 68(4):1-14.
Score: 0.011
-
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine. 1999 Oct 14; 18(5-6):531-9.
Score: 0.011
-
A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999 Aug; 180(2):397-403.
Score: 0.010
-
Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
Score: 0.010
-
Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2018 01 29; 36(5):606-614.
Score: 0.009
-
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
Score: 0.009
-
Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997 Jul; 15(10):1114-22.
Score: 0.009
-
Severe paroxysmal coughing and pleuritic pain in an adult. Hosp Pract (1995). 1995 Dec 15; 30(12):65-7.
Score: 0.008
-
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vaccine Immunol. 2016 01; 23(1):73-7.
Score: 0.008
-
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
Score: 0.008
-
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. J Infect Dis. 2015 Aug 15; 212(4):525-30.
Score: 0.008
-
Diurnal variation in responses to influenza vaccine. Chronobiol Int. 1995 Feb; 12(1):28-36.
Score: 0.008
-
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
Score: 0.008
-
Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Vaccine. 2014 Jun 12; 32(28):3548-54.
Score: 0.007
-
Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine. 2014 Feb 12; 32(8):1019-28.
Score: 0.007
-
Assessing agreement of repeated binary measurements with an application to the CDC's anthrax vaccine clinical trial. Int J Biostat. 2013 Jul 27; 9(1).
Score: 0.007
-
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15; 208(4):559-63.
Score: 0.007
-
Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial. Vaccine. 2012 Aug 31; 30(40):5875-9.
Score: 0.006
-
Perspectives on human microbiome research ethics. J Empir Res Hum Res Ethics. 2012 Jul; 7(3):1-14.
Score: 0.006
-
Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
Score: 0.006
-
Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
Score: 0.006
-
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008 Dec 08; 168(22):2405-14.
Score: 0.005
-
Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA. 2008 Oct 01; 300(13):1532-43.
Score: 0.005
-
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29; 26(32):4057-61.
Score: 0.005
-
Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol. 1988 Feb; 127(2):353-64.
Score: 0.005
-
A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
Score: 0.004
-
Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis. 2006 Jul 15; 43(2):151-7.
Score: 0.004
-
Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin. 2005 Nov-Dec; 1(6):239-44.
Score: 0.004
-
Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005 Oct 13; 353(15):1555-63.
Score: 0.004
-
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 02; 352(22):2271-84.
Score: 0.004
-
Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005 Feb 03; 23(11):1414-25.
Score: 0.004
-
Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis. 2004 Dec 01; 39(11):1715-8.
Score: 0.004
-
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004 Aug 01; 190(3):535-44.
Score: 0.004
-
The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis. 2003 May 15; 187(10):1571-80.
Score: 0.003
-
Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2003 Apr 11; 17(6):801-7.
Score: 0.003
-
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun. 2002 Mar; 70(3):1417-21.
Score: 0.003
-
Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002 Jan 15; 20(7-8):1099-105.
Score: 0.003
-
Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol. 1991 Feb 01; 133(3):296-304.
Score: 0.001